Wall Street Analysts Predict a 25.69% Upside in Embecta Corp. ( EMBC ) : Here's What You Should Know
The consensus price target hints at a 25.7% upside potential for Embecta Corp. (EMBC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) ( Nasdaq: EMBC ) , a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025.
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) EMBC, a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025.
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.
embecta Announces Quarterly Cash Dividend - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Embecta Corp. ( "embecta" ) EMBC has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.
embecta to Report Fiscal Third Quarter 2025 Financial Results
PARSIPPANY, N.J., July 24, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) , a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 ...
embecta to Report Fiscal Third Quarter 2025 Financial Results - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., July 24, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) EMBC, a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial ...
embecta to Participate in Investor Events
PARSIPPANY, N.J., May 27, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) , a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following ...
embecta to Participate in Investor Events - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., May 27, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) EMBC, a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:.
embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., May 22, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta". "The Company" ) EMBC, a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present ...
embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day
PARSIPPANY, N.J., May 22, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta". "The Company" ) ( Nasdaq: EMBC ) , a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation ...
Why Is Embecta Stock Falling On Friday? - Embecta ( NASDAQ:EMBC )
FY25 EPS guidance reaffirmed at $2.70-$2.90 vs. $2.80 consensus. Revenue forecast slightly lowered to $1.073 billion-$1.09 billion vs. $1.09 billion consensus. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on. Embecta Corp.
Embecta Corp. ( EMBC ) Tops Q2 Earnings Estimates
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 6.06% and 2.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., May 09, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) ( Nasdaq: EMBC ) , a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025.
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., May 09, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.
embecta Announces Quarterly Cash Dividend - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., May 09, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Embecta Corp. ( "embecta" ) EMBC has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.
Solventum ( SOLV ) Tops Q1 Earnings and Revenue Estimates
Solventum (SOLV) delivered earnings and revenue surprises of 12.61% and 3.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Embecta to host Analyst and Investor Day on May 22, 2025 - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., April 28, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) EMBC, a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City.
embecta to Report Fiscal Second Quarter 2025 Financial Results
PARSIPPANY, N.J., April 21, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) , a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, ...
BD Seeks Potential Buyers for Life Sciences Business Division
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
The FITTER Forward Expert Recommendations are an updated set of global best practices for insulin injection technique and education.
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
PARSIPPANY, N.J., April 01, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) , a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings.
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., April 01, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) EMBC, a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings.
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference
PARSIPPANY, N.J., Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( embecta ) ( Nasdaq: EMBC ) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET.
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business - Becton Dickinson ( NYSE:BDX )
Becton Dickinson plans to separate its Biosciences and Diagnostic Solutions unit, aiming for completion by fiscal 2026. BD reported Q1 2025 sales of $5.17B, up 9.8% YoY, beating estimates. Adjusted EPS of $3.43 topped the $2.98 consensus.
Embecta Corp. ( EMBC ) Tops Q1 Earnings and Revenue Estimates
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 44.44% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) EMBC, a global diabetes care company, today reported financial results for the three month period ended December 31, 2024.
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" or the "Company" ) ( Nasdaq: EMBC ) , a global diabetes care company, today reported financial results for the three month period ended December 31, 2024.
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.
embecta Announces Quarterly Cash Dividend - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of Embecta Corp. ( "embecta" ) EMBC has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock.
Pfizer ( PFE ) Beats Q4 Earnings and Revenue Estimates
Pfizer (PFE) delivered earnings and revenue surprises of 31.25% and 1.52%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit - Becton Dickinson ( NYSE:BDX )
Bank of America analysts estimate that spinning off Becton Dickinson's life sciences division could increase its value by up to 30%. Becton Dickinson previously spun off Embecta in April 2022, but the company's stock has since declined by about 60%. Get Wall Street's Hottest Chart Every Morning
embecta to Report Fiscal First Quarter 2025 Financial Results
PARSIPPANY, N.J., Jan. 23, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) ( Nasdaq: EMBC ) , a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, ...
embecta to Report Fiscal First Quarter 2025 Financial Results - Embecta ( NASDAQ:EMBC )
PARSIPPANY, N.J., Jan. 23, 2025 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( "embecta" ) EMBC, a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a ...
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Aehr Test System ( NASDAQ:AEHR ) , Ardent Health Partners ( NYSE:ARDT )
U.S. stock futures were higher this morning, with the Dow futures gaining over 150 points on Tuesday. Shares of Aehr Test Systems, Inc. AEHR fell sharply in today's pre-market trading after the company reported worse-than-expected financial results for the second quarter on Monday.
The Zacks Analyst Blog Highlights Doximity, BrightSpring Health Services and Embecta
Doximity, BrightSpring Health Services and Embecta are part of the Zacks top Analyst Blog.
3 Stocks Trading Near 52-Week High With Room to Rise Further
Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue.
3 Medical Services Stocks to Buy to Counter Labor Shortage Woes
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. However, healthcare staffing shortage is leading to an increase in labor wages.
Here's Why You Should Add Ensign Group Stock to Your Portfolio Now
ENSG should benefit from expanding facilities and growing footprint, leading to higher service revenues in the future.
4 Best-Bargain PEG Stocks That Value Investors Love
Here are four stocks that fit our screening criteria. These are GAP, EMBC, BLBD and ZIM.
embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- Embecta Corp. ( embecta ) ( Nasdaq: EMBC ) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Embecta Corp. ( EMBC )
Embecta Corp. (EMBC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - Baxter Intl ( NYSE:BAX ) , DexCom ( NASDAQ:DXCM )
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to "Attractive," believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
New Strong Buy Stocks for December 2nd
EMBC, TOST, MNDY, NTRS and MANU have been added to the Zacks Rank #1 (Strong Buy) List on December 2, 2024.
Best Value Stocks to Buy for December 2nd
EMBC, BLBD and ENVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 2, 2024.
This Dick's Sporting Goods Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Embecta ( NASDAQ:EMBC ) , Dick's Sporting Goods ( NYSE:DKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan analyst Adrian Heurta upgraded the rating for Martin Marietta Materials, Inc.
Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views - Alector ( NASDAQ:ALEC ) , Dick's Sporting Goods ( NYSE:DKS )
U.S. stocks traded mostly higher toward the end of trading, with the S&P 500 gaining around 0.5% on Tuesday. The Dow traded up 0.05% to 44,759.66 while the NASDAQ rose 0.59% to 19,166.93. The S&P 500 also rose, gaining, 0.47% to 6,015.37. Utilities shares jumped by 1.1% on Tuesday.
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps - Embecta ( NASDAQ:EMBC )
On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago. The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the consensus of $277 million.
